: £12.9 million (+27.4%), supported by synthetic biology.
The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25
Co-founder and CEO announced he will step down from his role and the board by the end of 2026. : £12
: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update
: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth : : Established a strategic collaboration with Cepheid (a
: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas.
: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. : £72
"5414X" is the RNS (Regulatory News Service) identifier for the released by Oxford Nanopore Technologies plc .